Losartan is a synthetic, potent, orally active drug that selectively binds to the AT1 receptor. It can block the corresponding physiological effects of angiotensin II synthesized from any source or by any route. Losartan and its pharmacologically active carboxylic acid metabolite (E-3174) can selectively act on the AT1 receptor without affecting the functions of other hormone receptors or important ion channels in the cardiovascular system, nor inhibiting angiotensin converting enzyme (kininase II) that degrades bradykinin.

This product is a second-generation oral sulfonylurea hypoglycemic drug. It is a highly active pancreatic beta cell agent that binds to specific receptors on the pancreatic beta cell membrane and can induce the production of appropriate amounts of insulin to lower blood sugar concentration.

This product is a long-acting tricyclic antihistamine that can relieve seasonal allergic rhinitis or non-nasal symptoms by selectively antagonizing peripheral H1 receptors.

This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased.

Inhibit gastric acid secretion